Lonza Biologics Inc.
Lonza Biologics Inc.
News Article | May 12, 2017
— Global Laboratory Chemicals Market by products (Molecular biology, Cytokine and chemokine testing, Carbohydrate analysis, Immunochemistry, Cell/tissue culture, Environment testing, and Biochemistry), by end-user applications (Biotechnology, Academic segments, Nonacademic segment, corporate segment): Forecast to 2027 Basically, laboratory chemicals are the compounds or substances that are used in chemical reaction to measure produce and detect other chemical substance. These are being used in the large scale for commercial applications and research purpose. The laboratory chemicals market will rise mainly due to significant increase in use of laboratory chemical in basic research combined with commercial applications. Moreover, growing interest of world scientific community in laboratory chemical is anticipated to escalate the growth in the market. Study Objectives of Laboratory Chemicals Market: • To provide detailed analysis of the market structure along with forecast for the next 10 years of segments and sub • segments of the global laboratory chemicals Market. • To provide insights about factors affecting the market growth. • To analyze the global laboratory chemicals Market based on various factors- price analysis, supply chain analysis, Porter’s five force analysis etc. • To provide historical and forecast revenues of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, and Rest of the World (ROW). • To provide country level analysis of the market with respect to the current market size and future prospects • To provide country level analysis of the market for segment by product types, and end-users. • To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market. • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global laboratory chemicals market. The global laboratory chemicals market is segmented into product types, and end-user applications. On the basis of product types the market is segmented into Molecular biology, Cytokine and chemokine testing, Carbohydrate analysis, Immunochemistry, Cell/tissue culture, Environment testing, and Biochemistry. On the basis of end-user applications it is segmented as Biotechnology, Academic segments, Nonacademic segment, corporate segment. The key players present in the global laboratory chemical market mainly includes • Lonza Biologics ltd. • PerkinElmer Inc. • BD Biosciences • bioMerieux • Beckman Coulter Inc. • CALTAG Laboratories • GE healthcare • EMD Chemicals Inc. • Life technologies Corporation • Meridian Life science Inc. • Shimadzu Biotech • Takara Bio Inc. The report covers Geographies such as: Request for Table of Content at https://www.marketresearchfuture.com/request-toc/923 The market research report for Laboratory Chemicals of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report provides deep insights into current market scenario, historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. For more information, please visit https://www.marketresearchfuture.com/reports/laboratory-chemicals-market
News Article | September 21, 2017
PALM BEACH, Fla.--(BUSINESS WIRE)--Chatham Lodging Trust (NYSE:CLDT), a hotel real estate investment trust (REIT) focused on investing in upscale, extended-stay hotels and premium-branded, select-service hotels, today announced that it has acquired the 131-room Hilton Garden Inn Portsmouth Downtown in N.H., for $43.5 million, or approximately $332,000 per room. “This gorgeous property is located in the absolute center of downtown Portsmouth, a beautiful, historic, waterfront community, and is a perfect complement to the Chatham portfolio,” said Jeffrey H. Fisher, Chatham’s chief executive officer and president. “The hotel enjoys the best location within downtown Portsmouth and benefits from strong, diversified demand arising from a great combination of leisure, corporate and government business related to a thriving naval yard. “Portsmouth is an extremely high barrier-to-entry market, and the city has done a fantastic job balancing growth and maintaining the integrity of this historic community,” he noted. “Portsmouth has enacted sweeping changes to zoning codes, which makes permitting and development even more stringent and highly problematic for new supply wanting to enter the downtown market. “We have a long, highly successful track record acquiring hotels in the upper Northeast corridor. Our knowledge and presence in the region greatly aided our diligence process and underwriting. Since acquisition, our Hampton Inn & Suites Portland, Maine has been one of our best performing assets and we believe the Portsmouth market, on a similar trajectory as Portland, also will be a strong performer,” Fisher concluded. Opened in June 2006, the Hilton Garden Inn Portsmouth Downtown was fully renovated within the past two years and will require no major capital investment until 2022. The hotel was constructed with a timeless design that adheres to strict local requirements and fits well with the city’s historic charm. Downtown Portsmouth is one of the region’s most popular tourist destinations, owing to its distinctive architecture, riverfront location and extensive array of retail and restaurant facilities. A one-hour drive from Boston, Mass., and Manchester, N.H., downtown Portsmouth is a thriving tourist destination with a confluence of natural seaside beauty, historic architecture and a walkable downtown with more than 75 restaurants, an active brewery scene and a booming arts and theater scene. Portsmouth has been lauded as a great travel destination by the likes of Travel and Leisure, The Boston Globe, The New York Times and the Chicago Tribune. Located less than two miles from the hotel across the harbor, Pease International Tradeport, a former air force base, is a world-class office and industrial park encompassing 3,000 acres and home to approximately 250 companies employing more than 10,000 people. The Tradeport is diverse with high-tech, bio tech, manufacturing, R&D and import/export companies, including seven Fortune 500 and 14 international businesses. Occupying 4 million square feet of space, major corporations, including Ingersoll Rand, Lonza Biologics, Fisher Scientific, Sig Sauer and Sprague Energy, are located in this vast corporate community. Additionally, companies such as Timberland, Liberty Mutual and Bottomline Technologies have a substantial presence in the Portsmouth area. Portsmouth Naval Shipyard is the U.S. government’s oldest, continuously operating naval shipyard. It is the largest regional employer, with almost 7,000 people after adding 650 positions in 2016 and approximately 500 more in 2017. The U.S. Navy recently received approval to expand its current fleet of 275 deployable ships to 355 over the next decade, which will further spur job and economic growth at the shipyard and the regional economy. “Whether it is hotels we own or hotels Island Hospitality operates, we have a significant presence in this area of the country,” highlighted Dennis Craven, Chatham’s chief operating officer and executive vice president. “We own a Hampton Inn and Suites in nearby Exeter, N.H., and Island Hospitality operates a Homewood Suites within Portsmouth. Having three Hilton-branded hotels in the market will position us to maximize room pricing and provide us with economies of scale to optimize profitability. “As we pointed out in our second quarter earnings release, we constantly seek to enhance, and ultimately grow, our investment portfolio through opportunistic recycling. We remain under contract to sell two hotels which we expect to close within the next 60 days. This acquisition reinvests a portion of those proceeds into a hotel that is younger, yields higher cash-on-cash returns and increases our portfolio RevPAR given its projected 2017 RevPAR of $163. The property’s projected RevPAR growth is higher than the hotels we are selling, as well as our overall portfolio RevPAR growth. Once proceeds from asset sales are fully reinvested, we expect these transactions to be accretive to our net asset value and FFO per share,” Craven said. Chatham funded the purchase through available cash and borrowings on its revolving credit facility. The hotel will be managed by Island Hospitality Management, which is 51 percent owned by Fisher. Chatham estimates it acquired the property at a year one net operating income capitalization rate of approximately eight percent. Chatham Lodging Trust is a self-advised, publicly-traded real estate investment trust focused primarily on investing in upscale extended-stay hotels and premium-branded, select-service hotels. The company owns interests in 134 hotels totaling 18,341 rooms/suites, comprised of 39 properties it wholly owns with an aggregate of 5,843 rooms/suites in 15 states and the District of Columbia and a minority investment in two joint ventures that own 95 hotels with an aggregate of 12,498 rooms/suites. Additional information about Chatham may be found at www.chathamlodgingtrust.com. This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about Chatham Lodging Trust, including statements regarding future plans, strategies, performance, acquisitions, capital expenditures, future operating results and the timing and composition of revenues, among others, and statements containing words such as “expects,” “believes” or “will,” which indicate that those statements are forward-looking. Except for historical information, the matters discussed in this press release are forward-looking statements that are subject to certain risks and uncertainties that could cause the actual results or performance to differ materially from those discussed in such statements. Additional risks are discussed in the company’s filings with the Securities and Exchange Commission.
News Article | September 11, 2017
TUSTIN, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies and through its proprietary R&D pipeline, today announced the appointment of Roger J. Lias, Ph.D., as the new president of Avid Bioservices, the company’s wholly-owned contract development and manufacturing organization (CDMO) subsidiary. Dr. Lias, who has more than 20 years of CDMO management experience, will also join Peregrine’s board of directors. In conjunction with this appointment, Steven King will step down from his role as president of Avid on September 25, 2017 and remain as president and chief executive officer of Peregrine. “We have been in the process of transforming the company from a research and development focused organization offering CDMO services to a pure play CDMO. We have been looking for someone with a breadth of experience in the biologics contract development and manufacturing industry. We are very pleased to have the opportunity to bring someone with Roger’s impressive track record within the CDMO industry to help guide expansion and growth of the business,” said Mr. King. “Roger has a solid track record of success in driving business expansion, growing revenues and building stockholder value. We are looking forward to seeing the positive impact Roger can have on the Avid business and I look forward to closely working with him to maintain the continuity of the business during the coming transition.” Throughout his career, Dr. Lias has held senior management positions at several leading CDMOs including Cytovance Biologics, KBI BioPharma, Diosynth RTP (formerly Covance Biotechnology Services) and Lonza Biologics. At each of these companies, he was primarily charged with overseeing commercial operations, including growing and diversifying their respective client bases. During this time, Dr. Lias’ achievements ranged from building start-up Cytovance’s contract process development and biopharmaceutical cGMP production business, to increasing revenues at Diosynth from $16 million to $120 million over a four-year period. Additionally, he has built a reputation as a highly regarded CDMO industry advocate who has contributed to the acceptance and growth of the biologics contract manufacturing market. Dr. Lias earned his Ph.D. from Clare College at the University of Cambridge in the United Kingdom. “As someone with a long history in the CDMO space, I was impressed by the level of sophistication of the current Avid operation ranging from the recently opened state-of-the-art Myford facility to the industry leading services and capabilities available to its clients,” said Dr. Lias. “The Avid team has successfully put the key pieces in place to allow the company to become a significant player in the rapidly expanding CDMO industry. I am excited work to build upon that foundation and help the company take the next important step in establishing itself as the CDMO of choice for high quality cGMP clinical and commercial manufacturing services.” Dr. Lias most recently served as executive director, head of global biologics business development for Allergan plc., where he was responsible for developing and executing strategies designed to support the company’s business development activities related to innovative biologics, biosimilars and complex injectable products. In this role, he was instrumental in identifying, structuring and negotiating a biosimilars co-development collaboration with Amgen for four oncology biosimilar monoclonal antibody products. Prior to Allergan, Dr. Lias was president and group commercial director for Eden Biodesign, an established biopharmaceutical contract manufacturer and consultancy and wholly-owned subsidiary of Eden Biopharma Group. During his time with Eden Biodesign, he successfully transitioned the company’s CDMO client base from early-stage biotechnology companies to established biotechnology and multinational pharmaceutical companies, while also playing a key role in the eventual sale of Eden Biopharma Group to Watson Pharmaceuticals (now Allergan). “We recently initiated a search for individuals with relevant biologics contract manufacturing experience as part of our efforts to expand and change the makeup of the board of directors as we move toward a focus on growing the Avid CDMO business. We were fortunate to identify Roger as an ideal candidate early in the process and he quickly established himself as the clear choice for not only joining the board but also as the candidate for president. He has had a long and successful career in the CDMO space, as well as a clear vision for achieving success for Avid in the near and long-term,” said David H. Pohl, member of the Peregrine board of directors and head of the company’s nominating committee. “We look forward to having Roger join the board and the contributions he can make to the continued success of the business.” Avid Bioservices was established out of Peregrine’s internal biologics manufacturing and development capabilities and began formal operations in January 2002. The company has grown from an internal support operation to a full service CDMO that manufactures bulk drug substance for products that are approved and marketed in over 18 countries by leading biopharma companies. Avid was recently recognized as a leading CDMO by Life Science Leader as a recipient of multiple 2017 Contract Manufacturing Leadership Awards for Quality, Reliability, Capabilities, Expertise and Compatibility. The company has an outstanding regulatory inspection history and state-of-the-art cGMP manufacturing facilities. Mr. King has served as president of Avid since its formation in addition to his role as president and CEO of Peregrine Pharmaceuticals since 2003. About Peregrine Pharmaceuticals, Inc. Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of patients by delivering high quality pharmaceutical products through its contract development and manufacturing organization (CDMO) services and through advancing and licensing its investigational immunotherapy and related products. Peregrine's in-house CDMO services, including cGMP manufacturing and development capabilities, are provided through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. The company is also working to evaluate its lead immunotherapy candidate, bavituximab, in combination with immune stimulating therapies for the treatment of various cancers, and developing its proprietary exosome technology for the detection and monitoring of cancer. For more information, please visit www.peregrineinc.com. About Avid Bioservices, Inc. Avid Bioservices, a wholly owned subsidiary of Peregrine Pharmaceuticals, provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With over 20 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. For more information about Avid, please visit www.avidbio.com.
News Article | September 25, 2017
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that two of its leading biologics analytical experts will be presenting workshops on the development and validation of bioassays at two upcoming conferences. At the BEBPA 10th Annual Bioassay Conference, to be held at The Radisson Blu Hotel, St. Julian's, Malta, on Sept. 27-29, 2017, Mike Merges, Director of Strategic Growth of Biologics Analytical Services and Mike Sadick, Ph.D., Principal Scientist, Biologics Analytical Services, Development, will host a daylong workshop, on Wednesday Sept. 27, titled “Make Your Bioassay Great…The First Time” covering a wide range of issues concerning the development and optimization of bioassays. The workshop will include an overview of the basic tools required for success: analyst training, critical reagent maintenance, laboratory/equipment set up, assay formats, cell maintenance, propagation and banking, as well as regulatory expectations for phase I/II/III clinical trials. Practical approaches to understanding the fundamental aspects of bioassays, including design of assay formats, system suitability and preparation for bioassay transfer, will also be discussed, alongside working effectively with a contract development and manufacturing organization. The second event, KNect365 Life Sciences' 21st annual Well Characterized Biologics & Biological Assays Conference, will take place at the Hilton Washington DC / Rockville Hotel & Executive Meeting Center, Rockville, Maryland on Oct. 25-27. Again, Mike Merges and Mike Sadick will host a full day’s workshop session, titled “Building a Better Bioassay: An Introduction to Bioassay Development” on Wednesday, Oct. 25. The topics covered will be similar to those discussed at the previous event, and will draw on case studies to highlight examples and share experiences in this area. For more information on these events, visit bebpa.org and lifesciences.knect365.com Dr. Sadick has an extensive background in cellular biology, cellular immunology, receptor signaling, molecular biology and biochemistry. He has more than 30 years’ experience in research and industry, having held positions at Genentech, Eli Lilly and Aptuit before joining Catalent in 2012. His current role sees him lead Catalent’s activities in potency assays, both cell-based and enzyme-linked immunosorbent assay (ELISA) based, as well as molecular biology (including cloning and quantitative polymerase chain reaction (qPCR)), and protein/protein binding assessment. He holds a bachelor’s degree in biology from John Hopkins University, and a master’s degree and doctorate, both in immunology, from the University of Washington. Mr. Merges joined Catalent in 2011 as Director of Catalent Biologics Analytical Services, focusing on the transfer, development, validation, and performance of bioassays, immunoassays, microbiological assays, and viral clearance assays. Before that, he was Associate Director of Bioservices for Lonza Biologics, and has also held positions at the University of Maryland’s Institute of Human Virology, the National Cancer Institute and Johns Hopkins University, where he conducted viral immunology research. He obtained his bachelor’s degree in microbiology from the Pennsylvania State University, and his master’s degree in microbiology/virology from Hood College. About Catalent Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2017 generated more than $2 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com
Mitton-Fry M.J.,Ohio State University |
Brickner S.J.,S. J. Brickner Consulting LLC. |
Hamel J.C.,Pfizer |
Barham R.,Pfizer |
And 20 more authors.
Bioorganic and Medicinal Chemistry Letters | Year: 2017
Novel (non-fluoroquinolone) inhibitors of bacterial type II topoisomerases (NBTIs) are an emerging class of antibacterial agents. We report an optimized series of cyclobutylaryl-substituted NBTIs. Compound 14 demonstrated excellent activity both in vitro (S. aureus MIC90 =0.125μg/mL) and in vivo (systemic and tissue infections). Enhanced inhibition of Topoisomerase IV correlated with improved activity in S. aureus strains with mutations conferring resistance to NBTIs. Compound 14 also displayed an improved hERG IC50 of 85.9μM and a favorable profile in the anesthetized guinea pig model. © 2017 Elsevier Ltd.
Kim S.-H.,Bristol Myers Squibb |
De Mas N.,Process Research and Development |
De Mas N.,Lonza Biologics Inc. |
Parlanti L.,Process Research and Development |
And 20 more authors.
Organic Process Research and Development | Year: 2011
We describe the synthesis, chromatographic purification, and isolation of the epothilone-folic acid conjugate BMS-753493, an investigational new drug candidate for the treatment of cancer. The main challenges for process development were the instability of BMS-753493 in aqueous solution, the design and optimization of the preparative chromatography, and the removal of phosphate salts and water from the purified material. The operating conditions of the batch chromatographic purification were optimized using a column adsorption model. The free-salt active pharmaceutical ingredient was isolated via the precipitation of its zwitterion following a careful determination of the isolation parameters that controlled thermal and pH-related decomposition. This process enabled the manufacturing of several batches (10-30 g) of cGMP quality BMS-753493. © 2011 American Chemical Society.
Zang R.,Ohio State University |
Zang R.,Genzyme |
Zhang X.,Ohio State University |
Zhang X.,Lonza Biologics Inc. |
And 2 more authors.
Process Biochemistry | Year: 2013
Cell-based high throughput proliferation and cytotoxicity assays are increasingly used in drug screening and bioprocess development. However, online monitoring of cell proliferation, pH, and dissolved oxygen (DO) has been a challenge in 3D cell-based assays. In this work, a 40-microwell bioreactor (40-MBR) system was developed from a 384-well plate for real-time, noninvasive monitoring of pH, DO, and cell proliferation in 3D microenvironments. Chinese hamster ovary (CHO) and MCF-07 breast cancer cells cultured in 40-MBR confirmed that the 40-MBR was capable of simultaneously monitoring DO and cell proliferation based on culture fluorescence and pH by measuring the absorbance of phenol red. Cytotoxicity studies of sodium butyrate on CHO cells demonstrated that 40-MBR with dynamic background fluorescence correction gave more reliable and highly reproducible growth kinetic data compared to conventional multiwells with static background correction. Furthermore, the dosage effects of two new anticancer drug candidates, 5,7-dihydroxy-2-(4-hydroxyphenyl)-8-[(E)-2- phenylethenyl]-3,4-dihydro-2H-1-benzopyran-4-one (DH-8P-DB) and 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-[(E)-2-phenylethenyl]-3,4-dihydro-2H-1- benzopyran-4-one (DH-6P-DB), on HT-29 colon cancer cells were assessed using the 40-MBR, and the results indicated that DH-6P-DB would be a more potent drug in treating colon cancer than DH-8P-DB. These studies demonstrated that 40-MBR could serve as a high throughput platform for screening potential cancer drugs in early-stage drug discovery. © 2012 Elsevier Ltd. All rights reserved.
Tripathi S.A.,Mascoma Corporation |
Tripathi S.A.,Oak Ridge National Laboratory |
Olson D.G.,Mascoma Corporation |
Olson D.G.,Dartmouth College |
And 20 more authors.
Applied and Environmental Microbiology | Year: 2010
We report development of a genetic system for making targeted gene knockouts in Clostridium thermocellum, a thermophilic anaerobic bacterium that rapidly solubilizes cellulose. A toxic uracil analog, 5-fluoroorotic acid (5-FOA), was used to select for deletion of the pyrF gene. The ΔpyrF strain is a uracil auxotroph that could be restored to a prototroph via ectopic expression of pyrF from a plasmid, providing a positive genetic selection. Furthermore, 5-FOA was used to select against plasmid-expressed pyrF, creating a negative selection for plasmid loss. This technology was used to delete a gene involved in organic acid production, namely pta, which encodes the enzyme phosphotransacetylase. The C. thermocellum Δpta strain did not produce acetate. These results are the first examples of targeted homologous recombination and metabolic engineering in C. thermocellum, a microbe that holds an exciting and promising future in the biofuel industry and development of sustainable energy resources. © 2010, American Society for Microbiology.
Erler A.,Lonza AG |
de Mas N.,Lonza Biologics Inc. |
de Mas N.,Bristol Myers Squibb |
Ramsey P.,University of New Hampshire |
Henderson G.,Lonza Biologics Inc.
Biotechnology Letters | Year: 2013
As part of the process-characterization campaign of a candidate vaccine product, a recently developed class of three-level designs-definitive-screening designs-was employed to select a quadratic model that describes the effect of six input process parameters, including protein concentration, formaldehyde-to-protein ratio, lysine concentration, reaction duration, pH, and reaction temperature, on a formylation protein-crosslinking reaction. This design requires only 17 experimental runs. The resulting model was then used to simulate 10,000 runs that account for the variability in the inputs expected on manufacturing scale. The extent of protein polymerization was predicted to be within specifications for all simulated runs, demonstrating the robustness of the unit operation for subsequent process validation and future commercial manufacturing. © 2012 Springer Science+Business Media Dordrecht.
Zhang X.,Ohio State University |
Zhang X.,Lonza Biologics Inc. |
Yang S.-T.,Ohio State University
Process Biochemistry | Year: 2011
An online, analytical technology was developed that utilized fluorescence to detect cells during an immobilized cell culture process. Chinese hamster ovary (CHO) cells that produced monoclonal antibodies (mAb) were transfected to express green fluorescent protein (GFP), and stable, fluorescence-positive cells were obtained by fluorescence-activated cell sorting (FACS). The immobilized cell culture process was then used to test the effects of sodium butyrate on cells. In this study, cells were cultured in porous, fibrous matrices that were placed in spinner flasks. A lab-scale, perfusion bioreactor with computer-controlled, online fluorescence sensors that continuously detected GFP fluorescence and quantified cell growth was utilized. In addition, the level of GFP fluorescence was used to predict mAb production in the culture without sampling for cell counting and protein analysis. Thus, non-invasive, fluorescence detection of cells provided a rapid, reliable and robust approach for developing an immobilized cell culture process. © 2011 Elsevier Ltd. All rights reserved.